Suppr超能文献

严重联合免疫缺陷患者骨髓移植后植入供体T细胞的耐受性

Tolerance of engrafted donor T cells following bone marrow transplantation for severe combined immunodeficiency.

作者信息

Keever C A, Flomenberg N, Brochstein J, Sullivan M, Collins N H, Burns J, Dupont B, O'Reilly R J

机构信息

Bone Marrow Transplantation Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.

出版信息

Clin Immunol Immunopathol. 1988 Sep;48(3):261-76. doi: 10.1016/0090-1229(88)90020-7.

Abstract

Patients transplanted for the treatment of severe combined immunodeficiency (SCID) frequently develop a unique state of split lymphoid chimerism. Such patients have T cells of donor origin, and non-T cells which are predominantly or exclusively of host origin. We have studied the reactivity of engrafted donor T cells to host and/or donor antigens in 12 patients transplanted for SCID, focusing on the characteristics of the tolerance to host and/or donor MHC antigens observed in nine of these patients who were recipients of T-cell-depleted, haploidentical parental bone marrow. In both proliferative and cytolytic assays, engrafted, donor-derived T cells were shown to be selectively nonreactive to histoincompatible host cells. This tolerance could not be ascribed to cells with suppressive activity in the engrafted T-cell population. T cells from a subset of patients, however, exhibited proliferative but not cytolytic reactivity to donor peripheral blood mononuclear cells. The responding cells were shown to be donor-derived CD3+ cells and were predominantly reactive to B-cell fractions from the donor. Two patients who received transplants from each parent in sequence engrafted T cells from one parent and had non-T cells of host, paternal, and maternal origin. The engrafted T cells proliferated weakly to B cells from the other parent, but were tolerant in cytolytic assays. Donor anti-donor reactivity was seen only in haploidentical split chimeras who had not been treated with cytotoxic drugs prior to T-cell engraftment. This proliferative reactivity toward donor may be due to an absence of donor derived Ia+ antigen presenting cells resident in the thymus of SCID patients at the time when the T-cell repertoire is being shaped.

摘要

接受移植治疗重症联合免疫缺陷(SCID)的患者经常会出现一种独特的分裂淋巴细胞嵌合状态。这类患者具有供体来源的T细胞,而非T细胞主要或完全是宿主来源的。我们研究了12例接受SCID移植患者中植入的供体T细胞对宿主和/或供体抗原的反应性,重点关注其中9例接受T细胞去除的单倍体同基因亲代骨髓移植患者中观察到的对宿主和/或供体MHC抗原的耐受特征。在增殖和细胞溶解试验中,植入的供体来源T细胞对组织不相容的宿主细胞表现出选择性无反应。这种耐受性不能归因于植入的T细胞群体中具有抑制活性的细胞。然而,一部分患者的T细胞对供体外周血单个核细胞表现出增殖反应,但无细胞溶解反应。反应细胞被证明是供体来源的CD3 +细胞,主要对来自供体的B细胞部分有反应。两名依次接受来自双亲移植的患者植入了来自一位亲代的T细胞,其非T细胞具有宿主、父系和母系来源。植入的T细胞对来自另一位亲代的B细胞增殖较弱,但在细胞溶解试验中具有耐受性。供体抗供体反应仅在T细胞植入前未接受细胞毒性药物治疗的单倍体同基因分裂嵌合体中出现。这种对供体的增殖反应可能是由于在T细胞库形成时,SCID患者胸腺中缺乏供体来源的Ia +抗原呈递细胞。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验